miRNA-146b-3p在早期非小细胞肺癌中的诊断价值

Diagnostic value of miRNA-146b-3p in early non-small cell lung cancer

摘要:

目的探讨miR-146b-3p在早期非小细胞肺癌、良性肺结节与健康人群外周循环血中的表达差异及诊断价值。方法通过RT-PCR测定118例早期非小细胞肺癌、42例良性肺结节与48例健康人群外周循环血中的6种miRNAs（miR-15b-5p、miR-17-5p、miR-19a-3p、miR-20a-5p、miR-92a-3p、miR-146b-3p）的相对表达量，并进行统计学分析评价其在早期的诊断价值。结果相较于良性肺结节患者与健康人群，miR-146b-3p在非小细胞肺癌患者外周循环血中呈显著过表达。用ROC曲线来评价miR-146b-3p的诊断价值，在肺癌与良性结节组中： miR-146b-3p的曲线下面积为0.77，当取临界值0.01时，灵敏度为75%，特异性为71%；在肺癌与健康人组中： miR-146b-3p的曲线下面积为0.93，当取临界值0.72时，灵敏度为89%，特异性为84%。Logistic回归模型表明： 在肺癌与良性结节组中，年龄与miR-146b-3p为独立危险因素，其ROC曲线下面积为0.81，当取临界值0.85时，灵敏度为65%，特异性为89%；在肺癌与良性结节组中，miR-19a-3p与miR-146b-3p为独立危险因素，其ROC曲线下面积为0.98，当取临界值0.90时，灵敏度为94%，特异性为95%。结论miR-146b-3p对早期非小细胞肺癌、良性肺结节与健康人群有一定鉴别意义，可作为临床一种新的血液标志物。

Abstract:

ObjectiveTo assess the diagnostic value of miR-146b-3p in peripheral blood for early non-small cell lung cancer (NSCLC). MethodsPeripheral blood samples were collected from 118 patients with early NSCLC, 42 patients with benign pulmonary nodules and 48 healthy subjects. Circulating miR-15b-5p, miR-17-5p, miR-19a-3p, miR-20a-5p, miR-92a-3p and miR-146b-3p were detected by real-time fluorescent quantitative PCR (RT-qPCR) and compared among different groups. ResultsThe expression of miR-146b-3p was significantly higher in NSCLC patients than that in patients with benign lung nodules and healthy controls. The area under the ROC curve (AUC) of miR-146b-3p in differential diagnosis between NSCLC and benign lung nodules was 0.77; with the cut-off value of 0.01, the sensitivity and specificity was 75% and 71%, respectively. The AUC of miR-146b-3p in differentiating early NSCLC patients from healthy subjects was 0.93; with the cut-off value of 0.72, the sensitivity and the specificity was 89% and 84%, respectively. Logistic regression model indicated that age and miR-146b-3p were independent risk factors for early NSCLC compared to benign lung nodules, and the AUC was 0.81, with the cut-off value of 0.85, the sensitivity and the specificity was 65% and 89%. MiR-19a-3p and miR-146b-3p were independent risk factors for early NSCLC compared to healthy controls, and the AUC was 0.98, with the cut-off value of 0.90, the sensitivity and specificity was 94% and 95%, respectively. ConclusionMiR-146b-3p can differentiate early NSCLC from benign lung nodules and healthy control, indicating that it might be used as a new biomarker for early diagnosis of non-small cell lung cancer.